Sun Pharmaceutical Industries Ltd Q1FY26 concall decoded: Generic empire, branded ambitions, and one big psoriasis bet
Opening Hook While India debates drug price caps and US politicians rage about pharma greed, Sun Pharma quietly flexes with ₹138,514 Cr in Q1FY26 revenue (+9.5% YoY). Gross margins touched a glowing 79.6% — even Big Tech would blush. Yet net profit slipped 20% (₹22,786 Cr vs ₹28,356 Cr YoY) thanks to impairments and restructuring charges that read like a Netflix mini-series (opioids, Taro, Concert, Nigeria forex). Adjusted profit? A neat ₹29,961 Cr (+5.7%). With Ilumya leading its ₹1.2 Bn Innovative Medicines arm and India business holding an 8.3% market share, Sun looks less like a generic giant and more like a specialty pharma powerhouse. But can it keep balancing generic cash cows with branded moonshots?
At a Glance • Revenue – ₹138,514 Cr (+9.5% YoY, still pumping cash) • EBITDA – ₹43,017 Cr (+19% YoY, margin expanded to 31%) • Net Profit – ₹22,786 Cr (-20% YoY, litigation hangover) • Adjusted Net Profit – ₹29,961 Cr (+6% YoY, clean sheet looks better) • R&D spend – 6.5% of sales (₹9,029 Cr, pipeline is the new PR)
Management’s Key Commentary “Our adjusted PAT grew 6% YoY.” Translation: Ignore the legal settlements, focus on the ‘adjusted’ fairy tale. “EBITDA margin expanded to 31.1%.” Translation: Cost cuts worked better than your diet plan. “Innovative Medicines form 20% of revenues.” Translation: Generics fund our fancy R&D hobbies. “We retained leadership in India with 8.3% market share.” Translation: Doctors still prescribe Sun like it’s paracetamol. “Our US dermatology pipeline remains robust.” Translation: Skin is still in. “R&D spend is 6.5% of sales.” Translation: Burning cash today to sell billion-dollar drugs tomorrow. “Sustainability is core to growth.” Translation: ESG slides keep investors calm.
Numbers Decoded
Metric
Value
Takeaway
Revenue – The Hero
₹138,514 Cr
Steady YoY growth across India, US, EM, RoW.
EBITDA – The Sidekick
₹43,017 Cr
Margins at 31% show pricing + cost control magic.
Net Profit – The Drama Queen
₹22,786 Cr
-20% YoY, weighed by one-offs. Adjusted PAT tells a prettier story.
Analyst Questions Q: Why the profit drop despite strong EBITDA? A: “Litigation/impairments impacted.” Translation: Lawyers earned more than scientists.
Q: How is Ilumya performing? A: “Sales at $681 Mn in
